AN AUDIENCE WITH

Daphne Koller

Daphne Koller didn’t anticipate becoming a drug hunter when she joined Stanford University as a professor of machine learning in 1995. But after stumbling into biology a few years later because of the novelty of the small but diverse data sets it offered, the field quickly drew her in. By 2016, she was the chief computing officer at Alphabet’s ageing-focused biotech Calico. She then founded the biotech insitro in 2018 to explicitly generate high-quality biological data sets at high throughput to enable the application of machine learning to drug discovery. She spoke with Asher Mullard about her vision for machine learning in drug discovery, the need to view data as a core asset of a business rather than a byproduct and how to foster computational excellence in biopharma.

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Nature Reviews Drug Discovery 18, 576-577 (2019)

doi: 10.1038/d41573-019-00115-7

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.